Treatment Outcomes of Patients with Multidrug-Resistant Tuberculosis: Concern to Bedaquiline: Authors' Reply

被引：0
|
作者：
Kang, Yewon [1 ]
Mok, Jeongha [2 ,3 ,4 ]
机构：
[1] Dongkang Med Ctr, Dept Internal Med, Ulsan, South Korea
[2] Pusan Natl Univ Hosp, Dept Internal Med, 179 Gudeok Ro, Busan 49241, South Korea
[3] Pusan Natl Univ, Sch Med, Busan, South Korea
[4] Pusan Natl Univ Hosp, Biomed Res Inst, Busan, South Korea
来源：
TUBERCULOSIS AND RESPIRATORY DISEASES | 2022年 / 85卷 / 01期
关键词：
D O I：
10.4046/trd.2021.0135
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
引用
收藏
页码：98 / 99
页数：2
相关论文
共 50 条
  • [1] Treatment Outcomes of Patients with Multidrug-Resistant Tuberculosis: Concern to Bedaquiline
    Putra, Oki Nugraha
    Hidayatullah, Affan Y. N.
    [J]. TUBERCULOSIS AND RESPIRATORY DISEASES, 2021, 84 (04) : 338 - 339
  • [2] Outcomes of Bedaquiline Treatment in Patients with Multidrug Resistant Tuberculosis
    Mbuagbaw, Lawrence
    Guglielmetti, Lorenzo
    Hewison, Catherine
    Bakare, Nyasha
    Bastard, Mathieu
    Caumes, Eric
    Frechet-Jachym, Mathilde
    Robert, Jerome
    Veziris, Nicolas
    Khachatryan, Naira
    Kotrikadze, Tinatin
    Hayrapetyan, Armen
    Avaliani, Zaza
    Schunemann, Holger J.
    Lienhardt, Christian
    [J]. EMERGING INFECTIOUS DISEASES, 2019, 25 (05) : 936 - 943
  • [3] Treatment outcomes among patients with multidrug-resistant tuberculosis Reply
    Orenstein, Evan W.
    Galvani, Alison P.
    [J]. LANCET INFECTIOUS DISEASES, 2010, 10 (04): : 215 - 216
  • [4] Multidrug-Resistant Tuberculosis and Bedaquiline
    Salfinger, Max
    Somoskovi, Akos
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (25): : 2435 - 2436
  • [5] Interim treatment outcomes in multidrug-resistant tuberculosis patients treated sequentially with bedaquiline and delamanid
    Lee, Hoon Hee
    Jo, Kyung-Wook
    Yim, Jae-Joon
    Jeon, Doosoo
    Kang, Hyungseok
    Shim, Tae Sun
    [J]. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2020, 98 : 478 - 485
  • [6] Outcomes of Multidrug-Resistant Tuberculosis Treated With Bedaquiline or Delamanid
    Hwang, Hyeontaek
    Kang, Hyungseok
    Kwon, Yong-Soo
    Jeon, Doosoo
    Shim, Tae Sun
    Yim, Jae-Joon
    [J]. CLINICAL INFECTIOUS DISEASES, 2021, 73 (08) : 1362 - 1369
  • [7] Treatment Outcomes of FluoroquinoloneResistant Multidrug-Resistant Tuberculosis: An Implication for Delamanid- Authors' Reply
    Kim, Saerom
    Mok, Jeongha
    [J]. TUBERCULOSIS AND RESPIRATORY DISEASES, 2024, 87 (02) : 209 - 211
  • [8] COST EFFECTIVENESS OF BEDAQUILINE FOR THE TREATMENT OF MULTIDRUG-RESISTANT TUBERCULOSIS
    Wolfson, L.
    Walker, A.
    Hettle, R.
    Lu, X.
    Kambili, C.
    Murungi, A.
    Knerer, G.
    [J]. VALUE IN HEALTH, 2014, 17 (07) : A595 - A595
  • [9] More on Treatment Outcomes in Multidrug-Resistant Tuberculosis Reply
    Lange, Christoph
    Guenther, Gunar
    van Leth, Frank
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (26): : 2611 - 2611
  • [10] BEDAQUILINE FOR THE TREATMENT OF PULMONARY, MULTIDRUG-RESISTANT TUBERCULOSIS IN ADULTS
    Gras, J.
    [J]. DRUGS OF TODAY, 2013, 49 (06) : 353 - 361
12345